Substance Use Outcomes Among Sexual and Gender Minority Individuals Living with HIV Following Residential Substance Use Treatment in Washington, DC.
Substance Use Outcomes Among Sexual and Gender Minority Individuals Living with HIV Following Residential Substance Use Treatment in Washington, DC.
复制标题
DOI：
10.1080/07347324.2023.2241419
复制
发表时间：
2023
影响因子：
0.9
通讯作者：
中科院分区：
文献类型：
--
作者：
这项研究探讨了性或性别少数（SGM）的地位如何影响物质使用（SU）的治疗结果，主要是非洲裔美国人和失业的艾滋病毒感染者样本。N = 60例受试者入组以禁欲为重点的住院SU治疗中心，随后接受门诊治疗。在12个月随访时，存活率（即未重复使用物质的患者）为37.6%（非SGM组）vs. 4.8%（SGM组）。SGM状态对重复使用的影响为0.54 log odds，p = 0.11，这意味着SGM与非SGM个体相比，重复使用物质的危害增加了71.8%。对于这两组，重复使用的频率保持稳定，与SU相关的问题随着时间的推移而减少。结果表明，一个潜在的临床相关的发现，SGM个人有可能增加风险的SU后，混合住院-门诊计划。ClinicalTrials.gov试用注册号：NCT 01351454。
This study explored how sexual or gender minority (SGM) status influenced substance use (SU) treatment outcomes in a predominantly African American and unemployed sample of people with HIV. N = 60 participants were enrolled in an abstinence-focused inpatient SU treatment center, followed by outpatient treatment sessions. At 12-months follow-up, the survival rate (i.e. those who did not reuse substances) was 37.6% (non-SGM group) vs. 4.8% (SGM group). The impact of SGM status on reuse was .54 log odds, p = .11, which translates to a 71.8% increase in the hazard of reusing substances for SGM vs. non-SGM individuals. For both groups, frequency of reuse remained stable and problems associated with SU decreased over time. Results suggest a potentially clinically relevant finding that SGM individuals have possible heigh-tened risk of SU after a mixed inpatient-outpatient program. ClinicalTrials.gov trial registration number: NCT01351454.